Sudden Cardiac Death in a Patient with Thrombotic Thrombocytopenic Purpura: A Case Report
Authors:
- Kikuaki YoshidaKYKikuaki Yoshida
- Shogo MurataSMShogo Murata
- Masaya MorimotoMMMasaya Morimoto
- Toshiki MushinoTMToshiki Mushino
- Ken TanakaKTKen Tanaka
- Yusuke YamashitaYYYusuke Yamashita
- Hiroki HosoiHHHiroki Hosoi
- Akinori NishikawaANAkinori Nishikawa
- Shinobu TamuraSTShinobu Tamura
- Kinta HatakeyamaKHKinta Hatakeyama
- Masanori MatsumotoMMMasanori Matsumoto
- Takashi SonokiTSTakashi Sonoki
Open Access
- 2 June 2022
- journal article
- case report
- Published by MDPI AG in Hematology Reports
- Vol. 14 (2) , 203-209
Abstract
A 49-year-old female was admitted to our hospital with malaise and gross hematuria. As ADAMTS13 (a disintegrin-like and metalloproteinase with thrombospondin type 1 motifs 13) activity was absent and the ADAMTS13 inhibitor was detected, she was diagnosed with acquired thrombotic thrombocytopenic purpura (TTP). In addition to plasma exchange and corticosteroid therapy, she received rituximab therapy for inhibitor boosting but died suddenly of a cardiac arrest on day 9. The postmortem revealed microvascular platelet thrombi in multiple organs. In this case, the deterioration of the patient’s clinical status was considered to have been caused by inhibitor boosting-induced systemic microvascular occlusion. In particular, her sudden death may have been due to cardiovascular microthrombosis. Since inhibitor boosting can cause TTP patients to deteriorate rapidly, it is crucial to manage TTP patients who undergo inhibitor boosting appropriately. The monitoring of cardiac complications in TTP patients may also be essential, especially in the acute phase.Keywords
This publication has 17 references indexed in Scilit:
- Efficacy and safety of rituximab in Japanese patients with acquired thrombotic thrombocytopenic purpura refractory to conventional therapyInternational Journal of Hematology, 2016
- Risk Factors for Autoimmune Diseases Development After Thrombotic Thrombocytopenic PurpuraMedicine, 2015
- Poor responder to plasma exchange therapy in acquired thrombotic thrombocytopenic purpura is associated with ADAMTS13 inhibitor boosting: visualization of an ADAMTS13 inhibitor complex and its proteolytic clearance from plasmaTransfusion, 2015
- An autopsy case of myocardial infarction due to idiopathic thrombotic thrombocytopenic purpuraDiagnostic Pathology, 2015
- Corticosteroids and rituximab as adjunctive treatments for thrombotic thrombocytopenic purpuraAmerican Journal of Hematology, 2012
- A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpuraBlood, 2011
- Rituximab for refractory and or relapsing thrombotic thrombocytopenic purpura related to immune‐mediated severe ADAMTS13‐deficiency: a report of four cases and a systematic review of the literatureEuropean Journal of Haematology, 2009
- Antibodies to von Willebrand Factor–Cleaving Protease in Acute Thrombotic Thrombocytopenic PurpuraNew England Journal of Medicine, 1998
- von Willebrand Factor–Cleaving Protease in Thrombotic Thrombocytopenic Purpura and the Hemolytic–Uremic SyndromeNew England Journal of Medicine, 1998
- Comparison of Plasma Exchange with Plasma Infusion in the Treatment of Thrombotic Thrombocytopenic PurpuraNew England Journal of Medicine, 1991